Idiopathic Inflammatory Myopathy Treatment Market Worth $930.6 Million by 2026

The global idiopathic inflammatory myopathy treatment market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights™ published this information in an upcoming report, titled, "Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing Autoimmune Myopathy (NAM), Others), By Treatment (Corticosteroids, Immunosuppressants, Intravenous Immunoglobulins, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026."

Urgent Need for Modern Therapeutics to Boost Growth

Nowadays, numerous new, modern therapies are emerging across the world. The demand for more effective therapeutics is also rising day by day. Earlier, the traditional treatment options had limitations for the doses of immunosuppressants and glucocorticoids. They could be used up to a certain extent. However, today’s innovative therapeutic options help in treating a wide range of myositis.

Moreover, as more and more difficult-to-treat cases of idiopathic inflammatory myopathy increased, mankind realized the dire need for state-of-the-art therapies. It further create da highunmet demand for treatment options. It is expected to be one of the most crucial idiopathic inflammatory myopathy treatment market growth drivers.

For More Information : https://www.fortunebusinessinsights.com/industry-reports/idiopathic-inflammatory-myopathy-treatment-market-100198

Polymyositis Segment to Lead: Rising Prevalence of this Myopathy

By disease type, the market is divided into necrotizing autoimmune myopathy (NAM), dermatomyositis (DM), inclusion body myositis (IBM),polymyositis (PM), and others. Out of these, the PM segment had acquired 44.4%idiopathic inflammatory myopathy treatment market share in 2018. It is expected to retain its leading position throughout the forecast period. It is likely to occur as PM is considered to be one of the highly occurring forms of myositis. It is also capable of causing disability in those people who do not seek medical treatment immediately. Besides, increasing prevalence of PM worldwide and its presence in numerous clinical pipeline by industry giants would propel the growth of this segment. The other segments have also contributed to the steady growth of the market.

North America Will Dominate Backed by New Product Launches

The market is geographically divided into Latin America, North America, the Middle East and Africa, Europe, and Asia Pacific. Out of these, North AmericageneratedUSD 312.4 millionidiopathic inflammatory myopathy treatment market revenue in 2018. It is anticipated to dominate the market during the forthcoming years. This growth is attributable to the rising number of new product launches and the rising incidence of several types of myositis. Apart from these, increasing medical expenditure and rising research and development activities in the region would drive growth. Besides, growing technological advancements and increasing awareness programs are likely to affect the market in North America positively.

Asia Pacific is projected to exhibit the highest market value in the coming years owing to the increasing awareness campaigns about various forms of myopathies. Additionally, rising disposableincome of the masses is, in turn,causing high healthcare expenditure. In advanced Asian countries, such as Japan, there is a rising prevalence of myositis. These countries are also utilizing advanced therapeutics to treat the condition. Europe is expected to showcase a considerable growth on account of the rising incidence ofmyopathies in multiple countries.

More Trending Topics from Fortune Business Insights :

Medical Transcription Software Market, Share, Growth, Sales and Drivers Analysis Research Report 2026

Medical Transcription Software Market Exhibit a CAGR of 16.5% from 2019-2026; Advent of Cost-effective Cloud-integrated Software to Provide Impetus to Growth, says Fortune Business Insights

Saurabh is a part of the very talented content team at Fortune Business Insights™. He is a highly-driven writer with extensive experience in market research.